FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2779089724> ?p ?o ?g. }

• W2779089724 endingPage "706" @default.
• W2779089724 startingPage "698" @default.
• W2779089724 abstract "To support vaccination programs in developing countries, a 4-dose vial presentation of pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) was developed. This study assessed immunologic non-inferiority and safety of the investigational PHiD-CV 4-dose versus licensed 1-dose vial presentation in infants.In this phase III, mono-center, observer-blind study in Bangladesh, 6-10-week-old infants were randomized 1:1 to receive PHiD-CV primary vaccination (at ages 6, 10, 18 weeks) and a booster dose (at age 9 months) with a 4-dose vial (with preservative, 4DV group) or 1-dose vial (preservative-free, 1DV group). DTPw-HBV/Hib was (co)-administered per study protocol and polio, measles and rubella vaccines as part of the national immunization program. Non-inferiority of PHiD-CV 4-dose versus 1-dose vial for each vaccine pneumococcal serotype (VT) and vaccine-related serotype 19A in terms of antibody geometric mean concentration (GMC) was assessed (criterion: upper limit of 2-sided 95% confidence interval of antibody GMC ratios [1DV/4DV] <2-fold). Immune responses were measured. Solicited, unsolicited and serious adverse events (AEs) were evaluated.Of 320 infants (160 per group) vaccinated during the primary vaccination phase, 297 received a booster. Non-inferiority was demonstrated for each VT and 19A. One month post-primary vaccination, for most VT, ≥97.9% of infants in each group had antibody concentrations ≥0.2 μg/mL; for 19A ≥ 80.1% reached this threshold. Pneumococcal antibody responses and opsonophagocytic activity for each VT and 19A were within similar ranges between groups after primary and booster vaccination, as were anti-protein D responses. Booster immune responses were observed in both groups. Reported AEs were within similar ranges for both presentations.Immunologic non-inferiority of PHiD-CV 4-dose vial (with preservative) versus PHiD-CV 1-dose vial (preservative-free) was demonstrated. Immune responses and reactogenicity following primary/booster vaccination were within similar ranges for both presentations. PHiD-CV 4-dose vial would help improve access and coverage in resource-limited countries. Clinical Trial Registry: NCT02447432." @default.
• W2779089724 created "2018-01-05" @default.
• W2779089724 creator A5007325612 @default.
• W2779089724 creator A5017583099 @default.
• W2779089724 creator A5044909063 @default.
• W2779089724 creator A5050660259 @default.
• W2779089724 creator A5052442355 @default.
• W2779089724 creator A5064812129 @default.
• W2779089724 creator A5073133122 @default.
• W2779089724 creator A5074727137 @default.
• W2779089724 creator A5084092871 @default.
• W2779089724 date "2018-01-01" @default.
• W2779089724 modified "2023-09-26" @default.
• W2779089724 title "Immunologic non-inferiority and safety of the investigational pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) 4-dose vial presentation compared to the licensed PHiD-CV 1-dose vial presentation in infants: A phase III randomized study" @default.
• W2779089724 cites W1973988048 @default.
• W2779089724 cites W1996423558 @default.
• W2779089724 cites W2008699472 @default.
• W2779089724 cites W2028948634 @default.
• W2779089724 cites W2038157412 @default.
• W2779089724 cites W2039251425 @default.
• W2779089724 cites W2044704048 @default.
• W2779089724 cites W2050224530 @default.
• W2779089724 cites W2051453885 @default.
• W2779089724 cites W2074074587 @default.
• W2779089724 cites W2092915795 @default.
• W2779089724 cites W2098211461 @default.
• W2779089724 cites W2102997711 @default.
• W2779089724 cites W2113826000 @default.
• W2779089724 cites W2121392872 @default.
• W2779089724 cites W2123962567 @default.
• W2779089724 cites W2127699766 @default.
• W2779089724 cites W2194514727 @default.
• W2779089724 cites W2592582632 @default.
• W2779089724 cites W2604470353 @default.
• W2779089724 cites W2611740721 @default.
• W2779089724 cites W4243607164 @default.
• W2779089724 cites W2134093180 @default.
• W2779089724 doi "https://doi.org/10.1016/j.vaccine.2017.12.034" @default.
• W2779089724 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29277353" @default.
• W2779089724 hasPublicationYear "2018" @default.
• W2779089724 type Work @default.
• W2779089724 sameAs 2779089724 @default.
• W2779089724 citedByCount "2" @default.
• W2779089724 countsByYear W27790897242019 @default.
• W2779089724 countsByYear W27790897242020 @default.
• W2779089724 crossrefType "journal-article" @default.
• W2779089724 hasAuthorship W2779089724A5007325612 @default.
• W2779089724 hasAuthorship W2779089724A5017583099 @default.
• W2779089724 hasAuthorship W2779089724A5044909063 @default.
• W2779089724 hasAuthorship W2779089724A5050660259 @default.
• W2779089724 hasAuthorship W2779089724A5052442355 @default.
• W2779089724 hasAuthorship W2779089724A5064812129 @default.
• W2779089724 hasAuthorship W2779089724A5073133122 @default.
• W2779089724 hasAuthorship W2779089724A5074727137 @default.
• W2779089724 hasAuthorship W2779089724A5084092871 @default.
• W2779089724 hasBestOaLocation W27790897241 @default.
• W2779089724 hasConcept C12590561 @default.
• W2779089724 hasConcept C126322002 @default.
• W2779089724 hasConcept C147789679 @default.
• W2779089724 hasConcept C159047783 @default.
• W2779089724 hasConcept C159654299 @default.
• W2779089724 hasConcept C185592680 @default.
• W2779089724 hasConcept C197934379 @default.
• W2779089724 hasConcept C203014093 @default.
• W2779089724 hasConcept C22070199 @default.
• W2779089724 hasConcept C2776438120 @default.
• W2779089724 hasConcept C2776925733 @default.
• W2779089724 hasConcept C2777704310 @default.
• W2779089724 hasConcept C2778866548 @default.
• W2779089724 hasConcept C2779301066 @default.
• W2779089724 hasConcept C2779583294 @default.
• W2779089724 hasConcept C2779592421 @default.
• W2779089724 hasConcept C2780801004 @default.
• W2779089724 hasConcept C2781253189 @default.
• W2779089724 hasConcept C501593827 @default.
• W2779089724 hasConcept C71924100 @default.
• W2779089724 hasConcept C72092618 @default.
• W2779089724 hasConcept C86803240 @default.
• W2779089724 hasConcept C89423630 @default.
• W2779089724 hasConceptScore W2779089724C12590561 @default.
• W2779089724 hasConceptScore W2779089724C126322002 @default.
• W2779089724 hasConceptScore W2779089724C147789679 @default.
• W2779089724 hasConceptScore W2779089724C159047783 @default.
• W2779089724 hasConceptScore W2779089724C159654299 @default.
• W2779089724 hasConceptScore W2779089724C185592680 @default.
• W2779089724 hasConceptScore W2779089724C197934379 @default.
• W2779089724 hasConceptScore W2779089724C203014093 @default.
• W2779089724 hasConceptScore W2779089724C22070199 @default.
• W2779089724 hasConceptScore W2779089724C2776438120 @default.
• W2779089724 hasConceptScore W2779089724C2776925733 @default.
• W2779089724 hasConceptScore W2779089724C2777704310 @default.
• W2779089724 hasConceptScore W2779089724C2778866548 @default.
• W2779089724 hasConceptScore W2779089724C2779301066 @default.
• W2779089724 hasConceptScore W2779089724C2779583294 @default.
• W2779089724 hasConceptScore W2779089724C2779592421 @default.
• W2779089724 hasConceptScore W2779089724C2780801004 @default.
• W2779089724 hasConceptScore W2779089724C2781253189 @default.
• W2779089724 hasConceptScore W2779089724C501593827 @default.

• next